Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 10 TresibaⓇ has gained around 5%-points market share over the last 12 months in the USA Weekly TRX volume market shares¹ in the USA glargine U100 Basal volume TRX MS1 70% 60% 50% 40% 30% 20% 10% 0% NN total basal TresibaⓇ LevemirⓇ glargine U300 - biosimilar glargine U100 39.0% 35.9% -22.0% 13.5% 10.5% Sep 2016 Sep 2018 Note: The graph does not show NPH, which accounts for the residual market share Source: IQVIA weekly Xponent Plantrak (*excludes Medicaid), 14 September 2018 TRX volume: Insulin volume in mega units (MU) associated with total number of prescriptions; VANTAGE FingerTip Formulary bridge, September 2018 MS: Market share 1 Excluding Medicaid, Medicaid represents ~12% of retail basal market volume TresibaⓇ launch in the USA Novo Nordisk basal volume market share is now at 35.9% with TresibaⓇ volume market share of 13.5%, resulting in a gain of around 5%-points over the last 12 months TresibaⓇ formulary access is above 80% for Commercial and Medicare Part D combined In April 2018, promotion of the updated TresibaⓇ label2 was initiated 2 TresibaⓇ label was updated in March 2018 to include a 40% reduction of severe hypoglycaemic events compared to insulin glargine U100 novo nordisk

View entire presentation